1. Home
  2. SBGI vs DBVT Comparison

SBGI vs DBVT Comparison

Compare SBGI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sinclair Inc.

SBGI

Sinclair Inc.

HOLD

Current Price

$13.60

Market Cap

998.0M

Sector

Industrials

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$14.16

Market Cap

948.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBGI
DBVT
Founded
1986
2002
Country
United States
France
Employees
N/A
90
Industry
Broadcasting
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
998.0M
948.8M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
SBGI
DBVT
Price
$13.60
$14.16
Analyst Decision
Buy
Buy
Analyst Count
5
7
Target Price
$22.00
$32.04
AVG Volume (30 Days)
528.5K
373.3K
Earning Date
04-30-2026
05-12-2026
Dividend Yield
6.56%
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
$3,169,000,000.00
$5,636,000.00
Revenue This Year
$12.37
$35.04
Revenue Next Year
N/A
$2,360.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
35.77
52 Week Low
$12.46
$8.80
52 Week High
$17.88
$26.19

Technical Indicators

Market Signals
Indicator
SBGI
DBVT
Relative Strength Index (RSI) 42.12 45.68
Support Level $13.12 $12.75
Resistance Level $14.81 $14.68
Average True Range (ATR) 0.63 0.73
MACD -0.02 0.14
Stochastic Oscillator 5.82 68.06

Price Performance

Historical Comparison
SBGI
DBVT

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: